Simultaneous determination of warfarin and 7-hydroxywarfarin in rat plasma by HPLC-FLD

Aref Zayed 1 , Wahby M. Babaresh 1 , Ruba S. Darweesh 2 ,  and Tamam El-Elimat 1
  • 1 Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, 22110, Irbid, Jordan
  • 2 Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, 22110, Irbid, Jordan

Abstract

In this study, high-performance liquid chromatography with fluorescence detection (HPLC-FLD) has been used for the first time, for direct determination of warfarin and its major metabolite, 7-hydroxywarfarin, in rat plasma. The simple and sensitive method was developed using Fortis® reversed-phase diphenyl column (150 × 4.6 mm, 3 μm) and a mobile phase composed of phosphate buffer (25 mmol L−1)/methanol/acetonitrile (70:20:10, V/V/V), adjusted to pH 7.4, at a flow rate of 0.8 mL min−1. The diphenyl chemistry of the stationary phase provided a unique selectivity for separating the structurally related aromatic analytes, warfarin and 7-hydroxywarfarin, allowing their successful quantification in the complex plasma matrix. The method was linear over the range 0.01–25 μg mL−1, for warfarin and 7-hydroxywarfarin, and was found to be accurate, precise and selective in accordance with US FDA guidance for bioanalytical method validation. The method was sensitive enough to quantify 0.01 μg mL−1 of warfarin and 7-hydroxywarfarin (LLOQ) using only 100 μL of plasma. The applicability of this method was demonstrated by analyzing samples obtained from rats after oral administration of a single warfarin dose, and studying warfarin and 7-hydroxywarfarin pharmacokinetics.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. A. M. Holbrook, J. A. Pereira, R. Labiris, H. McDonald, J. D. Douketis, M. Crowther and P. S. Wells, Systematic overview of warfarin and its drug and food interactions, Arch. Intern. Med. 165 (2005) 1095–1106; https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486574

  • 2. M. Wadelius, L. Chen, K. Downes, J. Ghori, S. Hunt, N. Eriksson, O. Wallerman, H. Melhus, C. Wadelius and D. Bentley, Common VKORC1 and GGCX polymorphisms associated with warfarin dose, Pharmacogen. J. 5 (2005) 262–270; https://doi.org/10.1038/sj.tpj.6500313

  • 3. N. H. Holford, Clinical pharmacokinetics and pharmacodynamics of warfarin, Clin. Pharmacokinet. 11 (1986) 483–504; https://doi.org/10.2165/00003088-198611060-00005

  • 4. J. G. Kelly and K. O’Malley, Clinical pharmacokinetics of oral anticoagulants, Clin. Pharmacokinet. 4 (1979) 1–15; https://doi.org/10.2165/00003088-197904010-00001

  • 5. A. Osman, C. Enström and T. L. Lindahl, Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype, Arch. Intern. Med. 18 (2007) 293–296; https://doi.org/10.1097/MBC.0b013e3280444bfd

  • 6. Bristol-Myers Squibb, Coumadin, 2006; http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s009lbl.pdf; last access date November 10, 2018.

  • 7. R. A. O’Reilly, Warfarin Metabolism and Drug-drug Interactions, in The New Dimensions of Warfarin Prophylaxis (Eds. S. Wessler, C. G. Becker and Y. Nemerson), Springer, Boston (MA) 1987, pp. 205–212.

  • 8. C. Guo, S. Xue, X. Zheng, Y. Lu, D. Zhao, X. Chen and N. Li, The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats, Xenobiotica 48 (2017) 400–406; https://doi.org/10.1080/00498254.2017.1306760

  • 9. L. S. Kaminsky and Z.-Y. Zhang, Human P450 metabolism of warfarin, Pharmacol. Ther. 73 (1997) 67–74; https://doi.org/10.1016/S0163-7258(96)00140-4

  • 10. M. Ufer, Comparative pharmacokinetics of vitamin K antagonists, Clin. Pharmacokinet. 44 (2005) 1227–1246; https://doi.org/10.2165/00003088-200544120-00003

  • 11. M. Ufer, B. Kammerer, J. Kirchheiner, A. Rane and J.-O. Svensson, Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography–mass spectrometry after solid-phase extraction, J. Chromatogr. B 809 (2004) 217–226; https://doi.org/10.1016/j.jchromb.2004.06.023

  • 12. Q. Zhou, W. P. Yau and E. Chan, Enantioseparation of warfarin and its metabolites by capillary zone electrophoresis, Electrophoresis 24 (2003) 2617–2626; https://doi.org/10.1002/elps.200305441

  • 13. Z. Zuo, S. K. Wo, C. M. Y. Lo, L. Zhou, G. Cheng and J. H. S. You, Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography–tandem mass spectrometry, J. Pharm. Biomed. Anal. 52 (2010) 305–310; https://doi.org/10.1016/j.jpba.2010.01.005

  • 14. L. D. Heimark, L. Wienkers, K. Kunze, M. Gibaldi, A. C. Eddy, W. F. Trager, R. A. O’Reilly and D. A. Goulart, The mechanism of the interaction between amiodarone and warfarin in humans, Clin. Pharmacol. Ther. 51 (1992) 398–407; https://doi.org/10.1038/clpt.1992.39

  • 15. A. H. Salem, B. Hu, K. J. Freise, S. K. Agarwal, D. S. Sidhu and S. L. Wong, Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 Inhibitor, and warfarin in healthy volunteers, Clin. Drug Invest. 37 (2017) 303–309; https://doi.org/10.1007/s40261-016-0485-9

  • 16. D. K. Kumar, D. G. Shewade, S. Parasuraman, S. Rajan, J. Balachander, B. V. S. Chandran and C. Adithan, Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy, J. Young Pharm. 5 (2013) 13–17; https://doi.org/10.1016/j.jyp.2013.02.001

  • 17. I. Locatelli, V. Kmetec, A. Mrhar and I. Grabnar, Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation, J. Chromatogr. B 818 (2005) 191–198; https://doi.org/10.1016/j.jchromb.2004.12.024

  • 18. W. Naidong and J. W. Lee, Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma, J. Pharm. Biomed. Anal. 11 (1993) 785–792; https://doi.org/10.1016/0731-7085(93)80070-H

  • 19. H. Takahashi, T. Kashima, S. Kimura, N. Muramoto, H. Nakahata, S. Kubo, Y. Shimoyama, M. Kajiwara and H. Echizen, Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection, J. Chromatogr. B 701 (1997) 71–80; https://doi.org/10.1016/S0378-4347(97)00346-0

  • 20. T. Lomonaco, S. Ghimenti, I. Piga, M. Onor, B. Melai, R. Fuoco and F. Di Francesco, Determination of total and unbound warfarin and warfarin alcohols in human plasma by high performance liquid chromatography with fluorescence detection, J. Chromatogr. A 1314 (2013) 54–62; https://doi.org/10.1016/j.chroma.2013.08.091

  • 21. A. Qayyum, M. H. Najmi, A. M. Khan, M. Abbas, A. K. Naveed and A. Jameel, Determination of S-and R-warfarin enantiomers by using modified HPLC method, Pak. J. Pharm. Sci. 28 (2015) 1315–1321.

  • 22. C. Huang, J. Yang, Y. Du and L. Miao, Measurement of free concentrations of highly protein-bound warfarin in plasma by ultra performance liquid chromatography–tandem mass spectrometry and its correlation with the international normalized ratio, Clin. Chim. Acta 393 (2008) 85–89; https://doi.org/10.1016/j.cca.2008.03.008

  • 23. D. R. Jones, G. Boysen and G. P. Miller, Novel multi-mode ultra performance liquid chromatography–tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma, J. Chromatogr. B 879 (2011) 1056–1062; https://doi.org/10.1016/j.jchromb.2011.03.022

  • 24. M.-J. Kwon, H.-J. Kim, J.-W. Kim, K.-H. Lee, K.-H. Sohn, H.-J. Cho, Y.-K. On, J.-S. Kim and S.-Y. Lee, Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application, Korean J. Lab. Med. 29 (2009) 515–523; https://doi.org/10.3343/kjlm.2009.29.6.515

  • 25. A. N. Shaik, R. Grater, M. Lulla, D. A. Williams, L. L. Gan, T. Bohnert and B. W. LeDuc, Comparison of enzyme kinetics of warfarin analyzed by LC–MS/MS QTrap and differential mobility spectrometry, J. Chromatogr. B 1008 (2016) 164–173; https://doi.org/10.1016/j.jchromb.2015.11.036

  • 26. Z.-Y. Zhang, B. M. King and Y. N. Wong, Quantitative liquid chromatography/mass spectrometry/mass spectrometry warfarin assay for in vitro cytochrome P450 studies, Anal. Biochem. 298 (2001) 40–49; https://doi.org/10.1006/abio.2001.5383

  • 27. Y. Wong and P. Davis, Analysis of warfarin and its metabolites by reversed-phase ion-pair liquid chromatography with fluorescence detection, J. Chromatogr. A 469 (1989) 281–291; https://doi.org/10.1016/S0021-9673(01)96463-5

  • 28. S. H. Lee, L. Field, W. N. Howald and W. F. Trager, High-performance liquid chromatography separation and fluorescence detection of warfarin and its metabolites by postcolumn acid/base manipulation, Anal. Chem. 53 (1981) 467–471; https://doi.org/10.1021/ac00226a019

  • 29. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), FDA Guidance: Guidance for Industry. Bioanalytical Method Validation, May 2018; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf; last access date June 15, 2018.

  • 30. C. Guo, S. Xue, X. Zheng, Y. Lu, D. Zhao, X. Chen and N. Li, The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats, Xenobiotica 48 (2018) 400–406; https://doi.org/10.1080/00498254.2017.1306760

OPEN ACCESS

Journal + Issues

Search